AzTrials
AzTrials

Polycystic Ovary SyndromeNCT02078505

Gut Microbiome in Patients With Polycystic Ovary Syndrome

A study testing diet in people with Polycystic Ovary Syndrome, run by Meir Medical Center at 1 site in Israel.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The polycystic ovary syndrome is intimately associated with body weight and nutrition.The genomic era did not bring a breakthrough to the understanding of the syndrome. The recent surge of studies on gut microbiome has raised the possibility that the specific diet, which often affect these women favorably, would… Read more about this study

Who is it for?
Ages 18 to 35 years, women onlyHealthy volunteers can take part
Conditions the study is for
Polycystic Ovary Syndrome
What is being tested?
diet
Could I receive a placebo?
No, everyone receives an active treatment
How many people
60 participants
Where
1 siteIsrael
Study dates
Apr 2014to Mar 2016
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 35 years
  • Women only
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Study group - no other etiologies for infertility

Who cannot join

  • Other etiologies for infertility

Trial locations and contacts

1 site in 1 country.

Izhar Ben Shlomo, MD contact

972-52-6124781

izhar.benshlomo@gmail.com

Israel1 site
  • Rakati Clinic

    Tiberias

    iZHAR bEN sHLOMO, md, 972-52-6124781, IZHAR.BENSHLOMO@gmail.com

Other trials in Israel

About this study

Official title: The Effect of Diet on the Microbiome of Women With Polycystic Ovary Syndrome

The polycystic ovary syndrome is intimately associated with body weight and nutrition.The genomic era did not bring a breakthrough to the understanding of the syndrome. The recent surge of studies on gut microbiome has raised the possibility that the specific diet, which often affect these women favorably, would change their gut microbiome. Hence, the investigators will examine their gut microbial population in comparison to normal ovulatory women and then examine whether a low carbohydrate diet causes favorable change in their gut microbial population.

Read the detailed description
  • Scientific Background

Infertility is a major health problem that affects up to 15% of married couples. About half of these cases are attributable to female factors, among which anovulation is the leading cause. About 5% of all women of reproductive age are anovulatory due to the polycystic ovarian syndrome (PCOS). In addition to its effect on fertility, PCOS causes major health and cosmetic problems and significantly affects quality of life in women. PCOS is associated with cardiovascular morbidity and Type 2 diabetes mellitus, but it is unclear whether these are caused by the ovarian dysfunction or result from a common denominator.

  • PCOS
  • The clinical picture:

The polycystic ovary syndrome consists of anovulation, acne, hirsutism (resulting from hyperandrogenism), and reversed serum LH to FSH ratio. A large proportion of women with PCOS are overweight, and a significant proportion of women with PCOS have decreased peripheral insulin sensitivity. The direct cause to this insulin resistance is still enigmatic. All these features place women with PCOS as a group of patients related to the metabolic syndrome. Baranova et al. (2011) even stated that "it seems appropriate to consider polycystic ovary syndrome as the ovarian manifestation of metabolic syndrome".

  • Genetics

Not all women with PCOS have affected relatives but familial clusters are common, and brothers of women with PCOS have high serum levels of the androgen dehydroepiandrosterone sulfate. The eventual clinical expression of PCOS results not only from genetic predisposition but also from nutritional factors. Family studies using several approaches of analysis suggested up to 40 candidate genes, possibly responsible to the syndrome. Among these were genes from the steroidogenic pathways, the gonadotrophin receptors signal transduction pathways, the insulin signal transduction pathway and growth factor signal transduction pathways. Except for some association of polymorphism in CYP11 with hyperandrogenism none of these candidate genes were definitively associated with PCOS. The inheritance pattern of PCOS is not clear, some evidence favor autosomal dominant mode while others do not support it. Recently the methionine 196 arginine polymorphism in exon 6 of the TNF receptor 2 gene (676 T-->G) was shown to be associated with hyperandrogenism and PCOS, but the genotype did not influence any clinical or biochemical variable related to hyperandrogenism or insulin sensitivity and was not associated with obesity. A role of Calpain 10 gene in PCOS susceptibility was also suggested, as was that of a variant LH receptor.

The sex hormone binding gene also showed promise but disappointed. The mode of X-chromosome inactivation appears to be associated with the risk of sisters for discordancy to PCOD, but no specific genes are implicated in this respect. As with many complex disorders, the heritability of polycystic ovarian syndrome has eluded investigators. Although familial aggregation studies have demonstrated clearly a genetic component to the syndrome, simple Mendelian models do not characterize its mode of inheritance. Instead, multiple loci and epigenetic modification may play a role in the phenotype. The candidate gene approach relies upon improved statistical and technological methods to analyze potential genes based on biologic plausibility. Pathways that affect steroidogenesis, insulin resistance, gonadotropin function, and obesity provide potential genes for investigation. Obstacles such as phenotypic variability, lack of a male phenotype, multiple attempts at analysis, and small sample sizes hamper these efforts. Genome wide Analysis has become the gold standard for the elucidation of the genetic background for many diseases. The most recent and comprehensive such analysis of PCOD vs. controls was conducted by Chen et al (2011), and some candidate gens were defined, but a mechanistic understanding of possible causality is still far away.

  • Gut Microbiota
  • General:

The post genomic era led to several breakthroughs in our understanding of human physiology. One of the more prominent is the realization that our alimentary tract harbors 100-fold more living (bacterial) cells than our own body has. This discovery was made possible by the ability to define the presence of a bacterial strain by its DNA signature, without the need to culture it. Furthermore, the definition of these strains allows their allocation to major taxonomic divisions, in turn enabling what is legitimately called "profiling" of gut bacterial population diversity. Thus a new term has been coined "microbiota" to designate the total population of our gut microbes. In addition, it is now also possible to define the presence of specified enzymes and enzyme families in the gut microbiota, enabling in turn an outline of overall gut microbial metabolic capacity. It is of major interest now to characterize the varying taxonomic and metabolic profiles, as they pertain to specified human pathologies and physiological states.

Once microbiota profile that is associated with specific human pathology is characterized, a key question arises as to which is the egg and which is the hen. Namely, which is causative, the pathological state or the microbiota that has been shown to be associated with it? On several issues recent studies proven the microbiota to be most likely causative, as experimental transplantation of microbiota to mice led to the development of a state which was reminiscent of the human disease. Yet the differences between microbiotas of human populations on various locations across the globe raises the likely possibility that ethnicity, diet and other environmental factors have a meaningful effect on gut microbiota. All told, the study of the association of gut microbiota with many human conditions could reveal major subjects of interest, mostly towards possible understanding of causality as well as suggestions as to future corrective measures.

  • Women

Women go through several major physiological transitions during their lifetime. The first is puberty, followed by conception and pregnancy, usually more than once in life, and the last is menopause. It is likely that these would be associated with dynamic changes in gut microbiota, as a pioneering study shown recently that pregnant women's gut microbiota is profoundly altered as compared to that in non-pregnant women. Furthermore, as evidence is accumulating regarding specific alteration of gut microbiota in several morbid states, it is likely that woman's pathologies, such as anovulatory infertility associated with PCOS, could be associated with specific alterations in gut microbiota profile.

Naturally, the "egg vs. hen" question is of importance should differences between anovulatory and ovulatory women will be found, and should be tackled almost at the outset.

  • Overall Study Objective Is there a difference in gut microbial population between normal ovulatory women and women who suffer from PCOS, and if there is, what is its role in the causation of the syndrome?

Specific Aims

  • Is there a difference in microbial population profile between women with PCOS and normal ovulatory women?
  • Can a carbohydrate-poor diet and physical activity induce a change in the gut microbial population of women with PCOS?

Detailed Study Design Specific Aim I: Is there a difference in microbial population profile between women with PCOS and normal ovulatory women? A group of 30 women who will be diagnosed with PCOS by the standard Rotterdam consensus criteria and 30 normal ovulatory women will provide stool samples during the 3-5 initial days of their menstrual bleeding. Serum hormone and metabolic profile will be obtained concomitantly.

Samples will be submitted to DNA sequencing in GGA laboratories (Prof. Dani Bercovich), using the technique described previously in. The resulting datasets will be analyzed in the laboratory of Dr. Omry Koren, the Faculty of Medicine in the Galil, using the method he previously used.

Caveats and Potential Pitfalls It is possible that gut microbita of the two groups will not show either a taxonomic difference or a difference in putative metabolic enzyme profile. Nevertheless, we assume that at least one of these two arms will yield a positive product, since the polycystic ovary shares characters with the metabolic syndrome, amply documented to portray a distinct microbial population profile in comparison to healthy individuals.

Specific Aim II: Can a carbohydrate-poor diet and physical activity induce a change in the gut microbial population of women with PCOS? A change in diet has been known for many years to favorably affect the ovulatory function of patients with PCOS, as well as alleviating some of the associated cosmetic concerns. Most significantly, it is the carbohydrate element of this diet which is central to this change, alongside with the addition of physical activity. We will prescribe a carbohydrate-poor diet (appended table) to the study group and a concomitant physical activity program (45 minutes brisk walk, 4-5 times a week). After two months of this change of lifestyle we will repeat hormonal and metabolic profile, as well as obtain a second stool sample. A secondary interest would be to examine whether there exists a difference in the microbiome between women who would succeed in the diet and those who would not, whether in the initial bacterial population profile or that which will result from the diet.

Being tested
diet
Keywords
Change in gut microbial population, polycystic ovary syndrome, gut microbiome, diet
Medical subject headings
Polycystic Ovary Syndrome

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • dietBehavioural

    Carbohydrate poor diet

Study groups in NCT02078505
Study groupRoleWhat they receive
PCOS after dietExperimentalPatients after 2 months of diet
Receives: Behavioral: diet
controlNo interventionOvulatory women

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. change in microbial population of the colon

    Measured: 2 months of diet

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Mar 2014 (estimated)
  2. Study startApr 2014
  3. Primary completionMar 2016 (estimated)
  4. Study completionMar 2016 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Single group
Masking
None (open label)
Enrolment
60 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02078505
Sponsor's protocol ID
PCOSGut
Status last verified
Mar 2014
First submitted
3 Mar 2014
Last updated
11 Mar 2014
Results posted
No
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

A study testing diet in people with Polycystic Ovary Syndrome, run by Meir Medical Center at 1 site in Israel.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 11 Mar 2014. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Israel. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Izhar Ben Shlomo, MD (972-52-6124781, izhar.benshlomo@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

change in microbial population of the colon (time frame: 2 months of diet). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Mar 2014.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in